Mutant KRAS inhibitors enter the scene of precision therapeutics for pancreatic cancer.

ABSTRACT:

SUBMITTER: Pollin G 

PROVIDER: S-EPMC11399826 | biostudies-literature | 2024 Aug

REPOSITORIES: biostudies-literature